Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Selective repression of myoD transcription by v-Myc prevents terminal differentiation of quail embryo myoblasts transformed by the MC29 strain of avian myelocytomatosis virus

Abstract

We have investigated the mechanism by which expression of the v-myc oncogene interferes with the competence of primary quail myoblasts to undergo terminal differentiation. Previous studies have established that quail myoblasts transformed by myc oncogenes are severely impaired in the accumulation of mRNAs encoding the myogenic transcription factors Myf-5, MyoD and Myogenin. However, the mechanism responsible for such a repression remains largely unknown. Here we present evidence that v-Myc selectively interferes with quail myoD expression at the transcriptional level. Cis-regulatory elements involved in the auto-activation of qmyoD are specifically targeted in this unique example of transrepression by v-Myc, without the apparent participation of Myc-specific E-boxes or InR sequences. Transiently expressed v-Myc efficiently interfered with MyoD-dependent transactivation of the qmyoD regulatory elements, while the myogenin promoter was unaffected. Finally, we show that forced expression of MyoD in v-myc-transformed quail myoblasts restored myogenin expression and promoted extensive terminal differentiation. These data suggest that transcriptional repression of qmyoD is a major and rate-limiting step in the molecular pathway by which v-Myc severely inhibits terminal differentiation in myogenic cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Alemà S, Tatò F . 1994 Sem. Cancer Biol. 5: 147–156

  • Amati B, Frank SR, Donjerkovic D, Taubert S . 2001 Bioch. Bioph. Acta 1471: M135–M145

  • Birchmayer C, Gherardi E . 1998 Trends Cell Biol. 8: 404–410

  • Crescenzi M, Crouch DH, Tatò F . 1994 J. Cell Biol. 125: 1137–1145

  • Crouch DH, Fisher F, Clark W, Jayaraman PS, Goding CR, Gillespie DAF . 1993 Oncogene 8: 1849–1855

  • Falcone G, Tatò F, Alemà S . 1985 Proc. Natl. Acad. Sci. USA 82: 426–430

  • Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F, Tyner L . 2001 Proc. Natl. Acad. Sci. USA 98: 4510–4515

  • Grandori C, Cowley SM, James LP, Eisenman RN . 2000 Annu. Rev. Cell Dev. Biol. 16: 653–699

  • Kretzner L, Blackwood EM, Eisenman RN . 1992 Curr. Top. Microbiol. Immunol. 182: 435–443

  • La Rocca SA, Grossi M, Falcone G, Alemà S, Tatò F . 1989 Cell 58: 123–131

  • La Rocca SA, Crouch DH, Gillespie DAF . 1994 Oncogene 9: 3499–3508

  • Lassar AB, Skapek SX, Novitch B . 1994 Curr. Opin. Cell Biol. 6: 788–794

  • Li L, Olson EN . 1992 Adv. Cancer Res. 58: 95–120

  • Maione R, Amati P . 1997 Biochim. Biophys. Acta 1332: 19–30

  • Malik S, Huang CF, Schmidt J . 1995 Eur. J. Biochem. 230: 88–96

  • Miner JH, Wold BJ . 1991 Mol. Cell. Biol. 11: 2842–2851

  • Molkentin JD, Olson EN . 1996 Curr. Opin. Genes Dev. 6: 453–455

  • Murry CE, Kay MA, Bartosek T, Hauschka SD, Schwartz SM . 1996 J. Clin. Invest. 98: 2209–2217

  • Pinney DF, de la Brousse FC, Faerman A, Shani M, Maruyama K, Emerson Jr CP . 1995 Dev. Biol. 170: 21–38

  • Pollerberg GE, Kuschel C, Zenke M . 1995 J. Neurosci. Res. 41: 427–442

  • Puri PL, Sartorelli V . 2000 J. Cell. Physiol. 185: 155–173

  • Russo S, Tatò F, Grossi M . 1997 Oncogene 14: 63–73

  • Tajbakhsh S, Buckingham ME . 1994 Proc. Natl. Acad. Sci. USA 91: 747–751

  • Zimmerman K, Yancopoulos GD, Collum RG, Smith RK, Kohl NE, Denis KA, Nau MM, Witte ON, Toran-Allerand D, Gee CE, Minna JD, Alt FW . 1986 Nature 319: 780–783

Download references

Acknowledgements

We thank S Alemà (CNR, Roma, Italy) for the adenoviral vectors, D Fischman (Cornell University, New York, USA) for the MF20 antibody, D Gillespie (CRC Beatson Laboratories, Glasgow, UK) for the 237 antibody, E Olson (UT Southwestern Medical Center, Dallas, USA) for the myogenin constructs, B Paterson (NIH, Bethesda, USA) for the anti-Myogenin antibody, G Piaggio (Istituto Regina Elena, Roma, Italy) for the M4 construct and M Zenke (MDC, Berlin, Germany) for the pmycER-ts-sea vector. This work was supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC), MURST (Cofin 1999) and CNR/MURST (Legge 95/95).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Milena Grossi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

La Rocca, S., Vannucchi, S., Pompili, M. et al. Selective repression of myoD transcription by v-Myc prevents terminal differentiation of quail embryo myoblasts transformed by the MC29 strain of avian myelocytomatosis virus. Oncogene 21, 4838–4842 (2002). https://doi.org/10.1038/sj.onc.1205586

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205586

Keywords

This article is cited by

Search

Quick links